Home > Oncology > ESMO 2020 > Lung Cancer > Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)

Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)

Conference
ESMO 2020
Several clinical trials have showed that combining an anti-CTLA-4 inhibitor and an anti-PD-(L)1 inhibitor increases the overall response compared with an anti-PD-(L)1 inhibitor alone. Bispecific antibodies could be a new way to simultaneously block CTLA-4 and PD-1. Until now, 2 types of immune checkpoint inhibitors have shown clinical effectivity against a broad range of tumours: anti-CTLA-4 inhibitors (e.g. ipilimumab and tremelimumab) and PD-(L)1 inhibitors (e.g. nivolumab, pembrolizumab, atezolizumab, avelumab). There is a rationale to combine these types of immune checkpoint inhibitors because anti-CTLA-4 inhibitors increase the expression of PD-L1 in some tumours and the combination of anti-CTLA-4 inhibition and PD-(L)1 inhibition favours effector T cell recruitment in preclinical tumour models [1]. In addition, several clinical trials have shown that combining an anti-CTLA-4 inhibitor and an anti-PD-(L)1 inhibitor increases the overall response comp...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on